27.06.2013 Views

Voie d'immunisation et séquence d'administration de l ... - TEL

Voie d'immunisation et séquence d'administration de l ... - TEL

Voie d'immunisation et séquence d'administration de l ... - TEL

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

tel-00827710, version 1 - 29 May 2013<br />

<strong>de</strong>livery of cell-associated antigen. As expected, i.v. immunization led to a more rapid<br />

priming. Surprisingly, while <strong>de</strong>layed kin<strong>et</strong>ically, i.d. immunization triggered a more robust<br />

and polyfunctional primary T cell response and a b<strong>et</strong>ter secondary response. In contrast, the<br />

route of immunization did not impact the diversity or the avidity of the population of<br />

responding T cells. Factors such as inflammation induced at the site of injection, subs<strong>et</strong>s of<br />

DC implicated, or persistence of antigen may all contribute to the differences observed.<br />

To follow the characterization of the endogenous CD8 + T cell response, we were interested in<br />

assessing the effectiveness of the combination of adjuvant with our antigen and, in particular,<br />

focus on un<strong>de</strong>rstanding the optimal timing for <strong>de</strong>livery, as the kin<strong>et</strong>ics of antigen presentation<br />

were <strong>de</strong>pen<strong>de</strong>nt on the route of immunization. We <strong>de</strong>monstrated that the optimal timing of<br />

adjuvant <strong>de</strong>livery was route of immunization-<strong>de</strong>pen<strong>de</strong>nt and that there was an optimal time<br />

window for adjuvant application to observe positive effects on cross-priming. We i<strong>de</strong>ntified<br />

some effects of poly I:C as well as type I IFN on DCs and T cells allowing us to propose a<br />

mo<strong>de</strong>l explaining why the timing of adjuvant <strong>de</strong>livery is crucial for optimal priming. Our<br />

study in a fundamental mo<strong>de</strong>l that combined antigen and adjuvant highlights multiple factors<br />

that are important to consi<strong>de</strong>r when several treatments are combined. The same kind of<br />

approaches used here in an established experimental mo<strong>de</strong>l of cross-presentation may also be<br />

used to compare combinatorial therapies and sequence of administration of several treatments<br />

in complexe diseases such as cancer or chronic viral diseases.<br />

Page 177 of 256

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!